



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel .: 022-2407 2249 / 2401 9025 (30 Lines)
Fax.: 022-2407 3462 / 2407 0144
Email: admin@aartidrugs.com
website: www.aartidrugs.com
CIN No.:L37060MH1984PLC055433

Ref: ADL/SE/2023-24/100
December 28, 2023

To,
Listing/ Compliance Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001

BSE CODE – 524348

Dear Sir/Madam,

To,
Listing/ Compliance Department
National Stock Exchange of India Limited,
“Exchange Plaza”, Bandra - Kurla Complex,
Bandra (E), Mumbai – 400051

NSE SYMBOL: AARTIDRUGS

Sub: - Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Pursuant to the provisions of Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform the exchange that the Company has received an administrative warning letter dated December 27, 2023 issued by SEBI regarding the non-disclosure in the event of closure of Company’s Sarigam Plant in the month of April 2022. Letter is appended below.

At that point of time, event was considered non-material as per the company policy and hence this event was not disclosed at that point of time. We shall continue to adhere all regulations.

There is no impact on financial, operation or other activities of the Company pursuant to the above-mentioned administrative warning letter.

You are requested to take the same on records.

Thanking you,

Yours faithfully,

FOR AARTI DRUGS LIMITED

RUSHIKESH DEOLE
COMPANY SECRETARY & COMPLIANCE OFFICER
ICSI M.No.: A54527



DEPUTY GENERAL MANAGER
Corporation Finance Department
Division of Supervision, Enforcement & Complaints – 1

BY EMAIL AND SPEED POST

SEBI/HO/CFD/SEC-1/OW/P/2023/ 52276 /1

December 27, 2023

Aarti Drugs Limited
Plot No N-198, MIDC, Tarapur,
Village Pamtembhi, Taluka Palghar,
Thane, Maharashtra, 401506
E-mail: <rushikesh.deole@aartidrugs.com>

Kind attention: Company Secretary and Compliance officer

Sir/Madam,

Subject: Administrative warning letter – Non-Compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

1. SEBI has observed violation of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“**LODR Regulations**”) by Aarti Drugs Limited (“**the company/ ADL**”) as per the details given below:
 - 1.1. ADL has failed to disclose the material information regarding order of Gujrat Pollution Control Board (GPCB) for closure of operations of Sarigam Plant which has substantial contribution during FYs 2020-21 and 2021-22 in the turnover as well as profits of the company defying the spirit of the disclosure requirements under Regulation 30 of the LODR Regulations. Thus, the company has failed to comply with Regulation 30(4)(i)(a) and Regulation 30(12) of LODR Regulations.
 - 1.2. Further, the Policy for Determination of Materiality of Any Event / Information of ADL (as available on the website of the company) is not updated in compliance with amended Regulation 30(4)(i)(c) of LODR Regulations applicable w.e.f. July 15, 2023.

Page 1 of 2



2. The aforesaid non-compliance is viewed seriously. You are hereby warned and advised to ensure compliance with all applicable provisions of LODR Regulations. Any such aberration in future would be viewed seriously and appropriate action would be initiated.
3. You are also advised to place this letter before your Board of Directors in its next meeting and disseminate the same to the stock exchange(s). The stock exchanges are advised to take note of the contents of the letter.

Yours faithfully,

Jitendra Kumar

Jitendra Kumar



Copy to -

1. NSE (via email)
2. BSE (via email)